Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

IMPORTANCE: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with antiplatelet (AP) drugs in addition to OAC, with or w...

詳細記述

書誌詳細
主要な著者: Fox, Keith A. A., Velentgas, Priscilla, Camm, A. John, Bassand, Jean-Pierre, Fitzmaurice, David A., Gersh, Bernard J., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., Dabrowski, Elizabeth, Luo, Kaiyi, Gibbs, Liza, Kakkar, Ajay K.
フォーマット: Online 論文 テキスト
言語:English
出版事項: American Medical Association 2020
主題:
Original Investigation
オンライン･アクセス:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137686/
https://www.ncbi.nlm.nih.gov/pubmed/32101311
http://dx.doi.org/10.1001/jamanetworkopen.2020.0107

インターネット

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137686/
https://www.ncbi.nlm.nih.gov/pubmed/32101311
http://dx.doi.org/10.1001/jamanetworkopen.2020.0107

類似資料